바이오스펙테이터

by Jongwon Jang

SK Biopharm has completely begun to list its securities.

SK Biopharm announced that they submitted a securities report to the Financial Services Commission for the listing of the KOSPI on 19th.

SK Biopharm will offer 19,578,310 shares for the listing. The estimated price of the public offering is 36,000 ~ 49,000 won, and the amount of the public offering is 704.8 billion ~ 959.3 billion won.

Demand forecasts will be made for domestic and foreign institutional investors for two days from June 17th to 18th, and applications for new listing will be completed within June after subscription from June 23rd to 24th. Main hosts are NH Investment & Securities Co. and Citigroup Global Market Securities Co., and co-hosts are Korea Investment & Securities Co. and Morgan Stanley.

Based on the research and development of new drugs and technological capabilities accumulated for 28 years since the SK Group, in 1993, began to find growth engines for SK Biopharm, they are challenging to develop innovative treatments for central nervous system diseases that have high unmet needs.

In particular, SK Biopharm has experience in developing new drugs, clinical trials, and global commercialization independently. The uniquely developed epilepsy drug "Cenobamate (U.S. product name: XCOPRI)" was approved by the US FDA in November 2019 and officially launched in the US market in May this year.

In addition, the technology-exported sleep disorder treatment "Soriamfetol (U.S. product name: Sunosi)" has already been sold in the US market and the firm is preparing to enter the market for it after obtaining a European approval.

SK Biopharm plans to use the publicly funded funds secured through the IPO as a source of growth resources for growth into a global comprehensive pharmaceutical company, including research and development of innovative new drugs and investment in commercialization.